Oculis Holding AG (OCS) Cash from Investing Activities (2022 - 2024)
Oculis Holding AG (OCS) posted quarterly Cash from Investing Activities of -$19.7 million for Q2 2024, down 738.58% quarter-over-quarter from -$2.3 million in Q1 2024.
Analysis
Oculis Holding AG (OCS) Cash from Investing Activities (2022 - 2024) Analysis & Trends
Oculis Holding AG's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$19.7 million for Q2 2024.
- In Q2 2024, Cash from Investing Activities changed N/A year-over-year to -$19.7 million; the TTM figure through Jun 2024 stood at -$464875.5 (changed N/A YoY), while the FY2025 annual figure was -$73.5 million, down 302.01% from the prior year.
- Cash from Investing Activities for Q2 2024 stood at -$19.7 million, down from -$2.3 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $25.9 million in Q4 2023, with the low at -$19.7 million in Q2 2024.
- The 3-year median for Cash from Investing Activities is -$2.0 million (2024), against an average of -$427938.7.
- Peak annual rise in Cash from Investing Activities reached 1744.57% in 2023, while the deepest fall reached 714.06% in 2023.
- Oculis Holding AG's Cash from Investing Activities stood at -$1.6 million in 2022, then soared by 1744.57% to $25.9 million in 2023, then slumped by 176.04% to -$19.7 million in 2024.
- Business Quant data shows OCS's Cash from Investing Activities at -$19.7 million in Q2 2024, -$2.3 million in Q1 2024, and $25.9 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -19.67 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | 25.86 Mn |
| Sep 30, 2023 | -4.32 Mn |
| Dec 31, 2022 | -1.57 Mn |
| Sep 30, 2022 | -530,153.80 |